EP2347762
Exendín tiil að meðhöndla sykursýki og minnka líkamsþyngd
Status:
EP Einkaleyfi ógilt eftir andmæliEP appl. date:
18.8.2006EP published:
8.5.2019EP application number:
10016112.4
EP translation filed:
29.5.2019Grant published:
15.6.2019EPO information:
European Patent Register
Max expiry date:
17.8.2026Expiry date:
17.8.2024
Title:
EXENDIN FOR TREATING DIABETES AND REDUCING BODY WEIGHT
Timeline
Today
18.8.2006EP application
8.5.2019EP Publication
29.5.2019Translation submitted
15.6.2019Registration published
17.8.2024Expires
Owner
Name:
Amylin Pharmaceuticals, LLCAddress:
9360 Towne Centre Drive, 92121, San Diego, CA, US
Name:
AstraZeneca Pharmaceuticals LPAddress:
1800 Concord Pike, Wilmington, DE, US
Inventor
Name:
Fineman, MarkAddress:
San Diego, CA, US
Name:
Macconell, LeighAddress:
San Diego, CA, US
Name:
Taylor, KristinAddress:
San Diego, CA, US
Agent
Name:
G.H. Sigurgeirsson ehf.Address:
Borgartúni 26, 105, Reykjavík,
Priority
Number:
709604 PDate:
19.8.2005Country:
US
Number:
779216 PDate:
3.3.2006Country:
US
Classification
Categories:
A61K 38/26, A61K 9/00, A61P 3/10, A61P 3/04
Annual fees
Number
Paid
Expires
Payer
Number: 14
Paid: 9.7.2019
Expires: 17.8.2020
Payer: Árnason Faktor
Number: 15
Paid: 8.7.2020
Expires: 17.8.2021
Payer: Árnason Faktor ehf.
Number: 16
Paid: 12.7.2021
Expires: 17.8.2022
Payer: Árnason Faktor ehf.
Number: 17
Paid: 5.7.2022
Expires: 17.8.2023
Payer: Árnason Faktor ehf.
Number: 18
Paid: 11.7.2023
Expires: 17.8.2024
Payer: Árnason Faktor ehf.